Literature DB >> 15193547

Bone turnover markers in patients with osteogenesis imperfecta.

Vania Braga1, Davide Gatti, Maurizio Rossini, Francesca Colapietro, Elia Battaglia, Ombretta Viapiana, Silvano Adami.   

Abstract

Osteogenesis imperfecta (OI) is a heterologous group of rare inherited bone disorders resulting from defect in collagen synthesis or function. In previous studies, bone turnover has been found either increased or low-normal. These contradictory results might result from the study population made of children with prior recent fractures. We measured serum total and bone alkaline phosphatase (total and bone AP) serum osteocalcin (sOC), serum type I collagen C-telopeptide breakdown products (sCTX), urinary free-deoxypyridinoline (ufDPD), and urinary cross-linked N-telopeptides of type I collagen (uNTX) in 39 male and 38 premenopausal patients with different types of OI aged between 18 and 51 years who had not experienced new clinical fracture during 12 months preceding the laboratory assessment. The study also includes a control group of 29 men and 26 women matched for age and gender. Most bone markers were 50-200% higher in patients than in controls. Only sCTX was comparable to that found in controls. From a sub-analysis of the data, a trend for higher bone resorption markers was observed for any OI type, but patients with OI type III and IV had significantly higher values in ufDPD and uNTX than patients with type I OI, and their sOC levels were not significantly higher than in controls. These results provide a strong rational for the use of anti-resorbing agent in OI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193547     DOI: 10.1016/j.bone.2004.02.023

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  15 in total

1.  Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

Authors:  L A Bradbury; S Barlow; F Geoghegan; R A Hannon; S L Stuckey; J A H Wass; R G G Russell; M A Brown; E L Duncan
Journal:  Osteoporos Int       Date:  2011-07-08       Impact factor: 4.507

2.  A novel COL1A2 C-propeptide cleavage site mutation causing high bone mass osteogenesis imperfecta with a regional distribution pattern.

Authors:  T Rolvien; U Kornak; J Stürznickel; T Schinke; M Amling; S Mundlos; R Oheim
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

3.  Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.

Authors:  G Brunetti; F Papadia; A Tummolo; R Fischetto; F Nicastro; L Piacente; A Ventura; G Mori; A Oranger; I Gigante; S Colucci; M Ciccarelli; M Grano; L Cavallo; M Delvecchio; M F Faienza
Journal:  Osteoporos Int       Date:  2016-02-08       Impact factor: 4.507

4.  Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.

Authors:  Paolo Tranquilli Leali; Massimo Balsano; Gianluca Maestretti; Matteo Brusoni; Veronica Amorese; Emanuele Ciurlia; Matteo Andreozzi; Gianfilippo Caggiari; Carlo Doria
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

5.  Osteogenesis imperfecta: a case with hand deformities.

Authors:  Bengi Oz; Nese Olmez; Asuman Memis
Journal:  Clin Rheumatol       Date:  2005-04-23       Impact factor: 2.980

Review 6.  Bone mass and mineralization in osteogenesis imperfecta.

Authors:  Nadja Fratzl-Zelman; Barbara M Misof; Klaus Klaushofer; Paul Roschger
Journal:  Wien Med Wochenschr       Date:  2015-07-25

7.  Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta.

Authors:  Kosei Hasegawa; Kyoko Kataoka; Masaru Inoue; Yoshiki Seino; Tsuneo Morishima; Hiroyuki Tanaka
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

8.  New mouse models for metabolic bone diseases generated by genome-wide ENU mutagenesis.

Authors:  Sibylle Sabrautzki; Isabel Rubio-Aliaga; Wolfgang Hans; Helmut Fuchs; Birgit Rathkolb; Julia Calzada-Wack; Christian M Cohrs; Matthias Klaften; Hartwig Seedorf; Sebastian Eck; Ana Benet-Pagès; Jack Favor; Irene Esposito; Tim M Strom; Eckhard Wolf; Bettina Lorenz-Depiereux; Martin Hrabě de Angelis
Journal:  Mamm Genome       Date:  2012-04-21       Impact factor: 2.957

9.  The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta.

Authors:  Ingmar Ipach; Torsten Kluba; Petra Wolf; Bertram Pontz; Falk Mittag
Journal:  Orthop Rev (Pavia)       Date:  2012-09-04

10.  Bone to pick: the importance of evaluating reference genes for RT-qPCR quantification of gene expression in craniosynostosis and bone-related tissues and cells.

Authors:  Xianxian Yang; Jodie T Hatfield; Susan J Hinze; Xiongzheng Mu; Peter J Anderson; Barry C Powell
Journal:  BMC Res Notes       Date:  2012-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.